Sara Dellasala

1.2k citations

33 papers · 695 indexed · h-index 11

Hematology top 2%
- Chronic Myeloid Leukemia Treatments 31
- Acute Myeloid Leukemia Research 7
Genetics top 2%
- Chronic Lymphocytic Leukemia Research 23
- Myeloproliferative Neoplasms: Diagnosis and Treatment 6
Rheumatology top 10%
- Eosinophilic Disorders and Syndromes 13
Oncology
- HER2/EGFR in Cancer Research 2
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 3
Immunology
- Mast cells and histamine 1

Co-authors: Hagop M. Kantarjian Gautam Borthakur Jörge E. Cortes Farhad Ravandi Tapan M. Kadia Guillermo Garcia‐Manero Elias Jabbour Sherry Pierce
Cited by: Hematology Genetics Rheumatology
Partner nations: United States Georgia Italy

In The Last Decade

Sara Dellasala

30 papers receiving 688 citations

Peers

Countries citing papers authored by Sara Dellasala

Since Specialization

Citations

This map shows the geographic impact of Sara Dellasala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Dellasala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Dellasala more than expected).

Fields of papers citing papers by Sara Dellasala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Dellasala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Dellasala. The network helps show where Sara Dellasala may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sara Dellasala, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sara Dellasala Line = papers co-authored together Sara Dellasala links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse Omer Karrar,Elias Jabbour,Jayastu Senapati,Fadi Haddad,Ghayas C. Issa,Koji Sasaki,Hussein A. Abbas,Sara Dellasala,Farhad Ravandi,Hagop M. Kantarjian,Nicholas J. Short	2024	1
2	Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase Fadi Haddad,Koji Sasaki,Lewis Nasr,Nicholas J. Short,Tapan M. Kadia,Sara Dellasala,Jörge E. Cortes,Franck E. Nicolini,Ghayas C. Issa,Elias Jabbour,Hagop M. Kantarjian	2024	8
3	Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase Fadi Haddad,Koji Sasaki,Jayastu Senapati,Shimin Hu,Sara Dellasala,Ghayas C. Issa,Elias Jabbour,Hagop Kantarjian	2024	3
4	The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors Elias Jabbour,Koji Sasaki,Fadi Haddad,Ghayas C. Issa,Guillermo Garcia‐Manero,Tapan M. Kadia,Nitin Jain,Musa Yılmaz,Courtney D. DiNardo,Keyur P. Patel,Rashmi Kanagal‐Shamanna,Richard Champlin,Issa F. Khouri,Sara Dellasala,Sherry Pierce,Hagop M. Kantarjian	2023	15
5	More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia Fadi Haddad,Koji Sasaki,Ghayas C. Issa,Kunhwa Kim,Jeffrey Skinner,Sara Dellasala,Yesid Alvarado,Alessandra Ferrajoli,Tapan M. Kadia,Musa Yılmaz,Naveen Pemmaraju,Guillermo Garcia‐Manero,Sherry Pierce,Elias Jabbour,Hagop Kantarjian	2022	2
6	Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia Álex Bataller,Koji Sasaki,Elias Jabbour,Ghayas C. Issa,Fadi Haddad,Jeffrey Skinner,Sara Dellasala,Guillermo Garcia‐Manero,Sherry Pierce,Hagop Kantarjian	2022	1
7	Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis Elias Jabbour,Koji Sasaki,Fadi Haddad,Ghayas C. Issa,Jeffrey Skinner,Sara Dellasala,Musa Yılmaz,Alessandra Ferrajoli,Prithviraj Bose,Philip A. Thompson,Yesid Alvarado,Nitin Jain,Guillermo Garcia‐Manero,Koichi Takahashi,Gautam Borthakur,Naveen Pemmaraju,Sherry Pierce,Hagop M. Kantarjian	2022	25
8	Long‐term results of frontline dasatinib in chronic myeloid leukemia Abhishek Maiti,Jörge E. Cortes,Keyur P. Patel,Lucia Masárová,Gautam Borthakur,Farhad Ravandi,Srđan Verstovšek,Alessandra Ferrajoli,Zeev Estrov,Guillermo Garcia‐Manero,Tapan M. Kadia,Graciela M. Nogueras‐González,Jeffrey Skinner,Rebecca Poku,Sara Dellasala,Rajyalakshmi Luthra,Elias Jabbour,Susan O’Brien,Hagop M. Kantarjian	2020	24
9	Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia Lucia Masárová,Jörge E. Cortes,Keyur P. Patel,Susan O’Brien,Graciela M. Nogueras‐González,Marina Konopleva,Srđan Verstovšek,Guillermo Garcia‐Manero,Alessandra Ferrajoli,Tapan M. Kadia,Farhad Ravandi‐Kashani,Gautam Borthakur,Sara Dellasala,Zeev Estrov,Elias Jabbour,Hagop M. Kantarjian	2020	13
10	A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy María Rosario Díaz Vázquez,Hagop M. Kantarjian,Gautam Borthakur,Susan O’Brien,Srđan Verstovšek,Farhad Ravandi,Alessandra Ferrajoli,Jörge E. Cortes,Tapan M. Kadia,William G. Wierda,Guillermo Garcia‐Manero,Sara Dellasala,Kathleen A Kehr,Sherry Pierce,Mary Beth Rios,Elias Jabbour	2019	3
11	Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up Lucia Masárová,Jörge E. Cortes,Keyur P. Patel,Susan O’Brien,Graciela M. Nogueras‐González,Marina Konopleva,Srđan Verstovšek,Guillermo Garcia‐Manero,Alessandra Ferrajoli,Tapan M. Kadia,Farhad Ravandi,Gautam Borthakur,Sara Dellasala,Elias Jabbour,Hagop M. Kantarjian	2018	1
12	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations Kiran Naqvi,Jörge E. Cortes,Raja Luthra,Susan O’Brien,William G. Wierda,Gautam Borthakur,Tapan M. Kadia,Guillermo Garcia‐Manero,Farhad Ravandi,Mary Beth Rios,Sara Dellasala,Sherry Pierce,Elias Jabbour,Keyur P. Patel,Hagop M. Kantarjian	2018	10
13	Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting Prajwal Boddu,Hagop M. Kantarjian,Abdul Rashid Shah,Gautam Borthakur,Srđan Verstovšek,Guillermo Garcia‐Manero,Naval Daver,Tapan M. Kadia,Farhad Ravandi,Nitin Jain,Ahmad Alhuraiji,Jan A. Burger,Steven M. Kornblau,Sara Dellasala,Sherry Pierce,Elias Jabbour,Jörge E. Cortes	2016	0
14	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes Preetesh Jain,Hagop M. Kantarjian,Koji Sasaki,Elias Jabbour,Jyothsna Dasarathula,Graciela Nogueras González,Srđan Verstovšek,Gautam Borthakur,William G. Wierda,Tapan M. Kadia,Sara Dellasala,Sherry Pierce,Farhad Ravandi,Susan O’Brien,Jörge E. Cortes	2016	14
15	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase Koichi Takahashi,Hagop M. Kantarjian,Yulong Yang,Koji Sasaki,Preetesh Jain,Sara Dellasala,Farhad Ravandi,Tapan M. Kadia,Naveen Pemmaraju,Naval Daver,Gautam Borthakur,Guillermo Garcia‐Manero,Elias Jabbour,Jörge E. Cortes	2016	10
16	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials Preetesh Jain,Hagop M. Kantarjian,Mona Lisa Alattar,Elias Jabbour,Koji Sasaki,Graciela Nogueras González,Sara Dellasala,Sherry Pierce,Srđan Verstovšek,William G. Wierda,Gautam Borthakur,Farhad Ravandi,Susan O’Brien,Jörge E. Cortes	2015	62
17	Pretreatment FMS like Tyrosine kinase-3 Internal Tandem duplication (FLT3-ITD) Mutant Allele Burden Does Not Predict Response to the Combination of Sorafenib and Azacytidine in Patients with Relapsed or High Risk Elderly Untreated Acute Myeloid Leukemia Binsah George,Jörge E. Cortes,Mónica Cabrero,Nitin Jain,Marina Konopleva,Michael Andreeff,Kadia Tapan,Sherry Pierce,Sara Dellasala,G. Borthakur,Elias Jabbour,Guillermo Garcia‐Manero,Hagop M. Kantarjian,Farhad Ravandi	2015	0
18	A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Naveen Pemmaraju,Hagop M. Kantarjian,Tapan M. Kadia,Jörge E. Cortes,Gautam Borthakur,Kate J. Newberry,Guillermo Garcia‐Manero,Farhad Ravandi,Elias Jabbour,Sara Dellasala,Sherry Pierce,Srđan Verstovšek	2014	60
19	Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation Maro Ohanian,Mark J. Levis,Stefan Faderl,Guillermo Garcia‐Manero,Elias Jabbour,Naval Daver,Sara Dellasala,Sherry Pierce,Jan A. Burger,Jörge E. Cortes,Hagop M. Kantarjian,Farhad Ravandi	2013	1
20	Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation Farhad Ravandi,Mona Lisa Alattar,Mark J. Levis,Guillermo Garcia‐Manero,Mary Ann Richie,Naval Daver,Stefan Faderl,Michael Andreeff,Gautam Borthakur,Jan A. Burger,Tapan M. Kadia,Michael R. Grunwald,Sara Dellasala,Jörge E. Cortes,Hagop M. Kantarjian	2012	1

About Sara Dellasala

Sara Dellasala is a scholar working on Hematology, Genetics and Rheumatology, having authored 33 papers that have together received 695 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (31 papers), Chronic Lymphocytic Leukemia Research (23 papers), Eosinophilic Disorders and Syndromes (13 papers), Acute Myeloid Leukemia Research (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers), Acute Lymphoblastic Leukemia research (3 papers), HER2/EGFR in Cancer Research (2 papers) and Mast cells and histamine (1 paper). The work is most often cited by research in Hematology (622 citations), Genetics (388 citations) and Rheumatology (149 citations). Sara Dellasala has collaborated with scholars based in United States, Georgia and Italy. Frequent co-authors include Hagop M. Kantarjian, Gautam Borthakur, Jörge E. Cortes, Farhad Ravandi, Tapan M. Kadia, Guillermo Garcia‐Manero, Elias Jabbour, Sherry Pierce, Jan A. Burger and Mona Lisa Alattar.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact